-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
PROCEPT BioRobotics (NASDAQ:PRCT) Sets New 1-Year High at $48.96
PROCEPT BioRobotics (NASDAQ:PRCT) Sets New 1-Year High at $48.96
PROCEPT BioRobotics Co. (NASDAQ:PRCT – Get Rating)'s stock price reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $48.96 and last traded at $48.40, with a volume of 8089 shares traded. The stock had previously closed at $44.87.
Analyst Ratings Changes
PRCT has been the topic of a number of analyst reports. KeyCorp initiated coverage on shares of PROCEPT BioRobotics in a research note on Friday, July 15th. They issued an "overweight" rating and a $47.00 target price on the stock. B. Riley initiated coverage on shares of PROCEPT BioRobotics in a research note on Thursday, June 23rd. They issued a "buy" rating and a $53.00 target price on the stock. Finally, Wells Fargo & Company initiated coverage on shares of PROCEPT BioRobotics in a research note on Friday, September 2nd. They issued an "overweight" rating and a $49.00 target price on the stock. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.50.
Get PROCEPT BioRobotics alerts:PROCEPT BioRobotics Stock Performance
The stock has a market capitalization of $2.15 billion and a price-to-earnings ratio of -19.35. The company has a quick ratio of 15.27, a current ratio of 16.01 and a debt-to-equity ratio of 0.22. The stock's 50-day simple moving average is $38.53 and its 200 day simple moving average is $35.53.
PROCEPT BioRobotics (NASDAQ:PRCT – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.06. PROCEPT BioRobotics had a negative net margin of 138.49% and a negative return on equity of 26.41%. Analysts expect that PROCEPT BioRobotics Co. will post -1.83 earnings per share for the current fiscal year.Insider Transactions at PROCEPT BioRobotics
In other news, Director Thomas M. Krummel sold 20,000 shares of the company's stock in a transaction that occurred on Tuesday, June 21st. The shares were sold at an average price of $35.98, for a total transaction of $719,600.00. Following the transaction, the director now directly owns 82,920 shares in the company, valued at $2,983,461.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 40.80% of the stock is owned by company insiders.
Hedge Funds Weigh In On PROCEPT BioRobotics
A number of large investors have recently modified their holdings of the stock. US Bancorp DE acquired a new position in PROCEPT BioRobotics in the second quarter valued at approximately $37,000. Amalgamated Bank acquired a new position in PROCEPT BioRobotics in the first quarter valued at approximately $39,000. Shell Asset Management Co. acquired a new position in PROCEPT BioRobotics in the second quarter valued at approximately $102,000. MetLife Investment Management LLC acquired a new position in PROCEPT BioRobotics in the first quarter valued at approximately $175,000. Finally, Quantbot Technologies LP acquired a new position in PROCEPT BioRobotics in the second quarter valued at approximately $178,000. 76.23% of the stock is currently owned by institutional investors and hedge funds.
About PROCEPT BioRobotics
(Get Rating)
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Read More
- Get a free copy of the StockNews.com research report on PROCEPT BioRobotics (PRCT)
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
- These Two Undervalued Stocks Are Ready To Rocket Higher
- GameStop Stock Just Flashed A Buy Signal
- Are Hidden Gems Lurking Among Chemical & Fertilizer Stocks?
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.
PROCEPT BioRobotics Co. (NASDAQ:PRCT – Get Rating)'s stock price reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $48.96 and last traded at $48.40, with a volume of 8089 shares traded. The stock had previously closed at $44.87.
納斯達克(股票代碼:PRCT-GET Rating)週四午盤交易中,普羅塞特生物機器人公司的股價創下52周新高。該股盤中一度漲至48.96美元,最新報48.4美元,成交量為8,089股。該股此前收盤報44.87美元。
Analyst Ratings Changes
分析師評級發生變化
PRCT has been the topic of a number of analyst reports. KeyCorp initiated coverage on shares of PROCEPT BioRobotics in a research note on Friday, July 15th. They issued an "overweight" rating and a $47.00 target price on the stock. B. Riley initiated coverage on shares of PROCEPT BioRobotics in a research note on Thursday, June 23rd. They issued a "buy" rating and a $53.00 target price on the stock. Finally, Wells Fargo & Company initiated coverage on shares of PROCEPT BioRobotics in a research note on Friday, September 2nd. They issued an "overweight" rating and a $49.00 target price on the stock. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.50.
PRCT一直是許多分析師報告的主題。KeyCorp在7月15日星期五的一份研究報告中啟動了對Procept BioRobotics股票的報道。他們對該股的評級為“增持”,目標價為47.00美元。B.萊利在6月23日星期四的一份研究報告中對Procept BioRobotics的股票進行了報道。他們對該股的評級為“買入”,目標價為53.00美元。最後,富國銀行在9月2日星期五的一份研究報告中啟動了對Procept BioRobotics股票的報道。他們對該股的評級為“增持”,目標價為49.00美元。一名分析師對該股的評級為持有,七名分析師對該公司的評級為買入。根據MarketBeat的數據,該公司目前的共識評級為“適度買入”,共識目標價為43.50美元。
PROCEPT BioRobotics Stock Performance
Procept BioRobotics股票表現
The stock has a market capitalization of $2.15 billion and a price-to-earnings ratio of -19.35. The company has a quick ratio of 15.27, a current ratio of 16.01 and a debt-to-equity ratio of 0.22. The stock's 50-day simple moving average is $38.53 and its 200 day simple moving average is $35.53.
該股市值21.5億美元,市盈率為-19.35倍。該公司的速動比率為15.27,流動比率為16.01,債務權益比率為0.22。該股的50日簡單移動均線切入位為38.53美元,200日簡單移動均線切入位為35.53美元。
Insider Transactions at PROCEPT BioRobotics
Procept BioRobotics的內幕交易
In other news, Director Thomas M. Krummel sold 20,000 shares of the company's stock in a transaction that occurred on Tuesday, June 21st. The shares were sold at an average price of $35.98, for a total transaction of $719,600.00. Following the transaction, the director now directly owns 82,920 shares in the company, valued at $2,983,461.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 40.80% of the stock is owned by company insiders.
其他新聞方面,董事託馬斯·M·克魯梅爾在6月21日(星期二)的一筆交易中出售了2萬股該公司股票。這些股票的平均價格為35.98美元,總成交額為719,600.00美元。交易完成後,董事現在直接擁有該公司82,920股,價值2,983,461.60美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可在美國證券交易委員會網站上查閲。40.80%的股份由公司內部人士持有。
Hedge Funds Weigh In On PROCEPT BioRobotics
對衝基金參與Procept BioRobotics
A number of large investors have recently modified their holdings of the stock. US Bancorp DE acquired a new position in PROCEPT BioRobotics in the second quarter valued at approximately $37,000. Amalgamated Bank acquired a new position in PROCEPT BioRobotics in the first quarter valued at approximately $39,000. Shell Asset Management Co. acquired a new position in PROCEPT BioRobotics in the second quarter valued at approximately $102,000. MetLife Investment Management LLC acquired a new position in PROCEPT BioRobotics in the first quarter valued at approximately $175,000. Finally, Quantbot Technologies LP acquired a new position in PROCEPT BioRobotics in the second quarter valued at approximately $178,000. 76.23% of the stock is currently owned by institutional investors and hedge funds.
一些大型投資者最近調整了對該股的持有量。US Bancorp DE在第二季度收購了Procept BioRobotics的一個新頭寸,價值約3.7萬美元。合併銀行在第一季度收購了Procept BioRobotics的一個新頭寸,價值約3.9萬美元。殼牌資產管理公司在第二季度收購了Procept BioRobotics的一個新頭寸,價值約為102,000美元。大都會人壽投資管理公司在第一季度收購了Procept BioRobotics的一個新頭寸,價值約為17.5萬美元。最後,Quantbot Technologies LP在第二季度收購了Procept BioRobotics的一個新頭寸,價值約為17.8萬美元。76.23%的股票目前由機構投資者和對衝基金持有。
About PROCEPT BioRobotics
關於Procept BioRobotics
(Get Rating)
(獲取評級)
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Procept BioRobotics公司是一家外科機器人公司,開發泌尿外科變革性解決方案。該公司開發、製造和銷售AquaBeam機器人系統,這是一種圖像引導的外科機器人系統,用於治療良性前列腺增生症(BPH)的微創泌尿外科手術。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on PROCEPT BioRobotics (PRCT)
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
- These Two Undervalued Stocks Are Ready To Rocket Higher
- GameStop Stock Just Flashed A Buy Signal
- Are Hidden Gems Lurking Among Chemical & Fertilizer Stocks?
- 免費獲取StockNews.com關於Procept BioRobotics(PRCT)的研究報告
- 安相能源有足夠的動力繼續提高動力嗎?
- 獨一無二的氫燃料電池庫存
- 這兩隻被低估的股票已經做好了進一步衝高的準備
- GameStop股票剛剛閃爍了買入信號
- 化工和化肥庫存中是否隱藏着寶藏?
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Procept BioRobotics日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Procept BioRobotics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧